StockData
Entera Bio Ltd. logo

Entera Bio Ltd. (ENTX) stock

ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$3.26+0.26 (+8.67%)

Close on Nov 18, 2026Market cap $564.44MP/E –Yield –

Entera Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Entera Bio's operating income for the twelve months ending Jun 30, 2026 was -$14.40M. For fiscal 2025 it was -$11.53M. The highest annual figure on record is -$5.37M in fiscal 2016.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.53M–
FY2024Dec 31, 2024-$9.59M–
FY2023Dec 31, 2023-$8.89M–
FY2022Dec 31, 2022-$13.02M–
FY2021Dec 31, 2021-$12.22M–
FY2020Dec 31, 2020-$11.17M–
FY2019Dec 31, 2019-$11.45M–
FY2018Dec 31, 2018-$10.86M–
FY2017Dec 31, 2017-$11.34M–
FY2016Dec 31, 2016-$5.37M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.56M–
Q1 FY2026Mar 31, 2026-$3.54M–
Q4 FY2025Dec 31, 2025-$3.04M–
Q3 FY2025Sep 30, 2025-$3.26M–
Q2 FY2025Jun 30, 2025-$2.67M–
Q1 FY2025Mar 31, 2025-$2.56M–
Q4 FY2024Dec 31, 2024-$2.34M–
Q3 FY2024Sep 30, 2024-$3.02M–
Q2 FY2024Jun 30, 2024-$2.17M–
Q1 FY2024Mar 31, 2024-$2.06M–
Q4 FY2023Dec 31, 2023-$1.96M–
Q3 FY2023Sep 30, 2023-$2.39M–
Q2 FY2023Jun 30, 2023-$2.33M–
Q1 FY2023Mar 31, 2023-$2.21M–
Q4 FY2022Dec 31, 2022-$3.07M–
Q3 FY2022Sep 30, 2022-$2.87M–
Q2 FY2022Jun 30, 2022-$3.25M–
Q1 FY2022Mar 31, 2022-$3.84M–
Q4 FY2021Dec 31, 2021-$4.09M–
Q3 FY2021Sep 30, 2021-$3.22M–
Q2 FY2021Jun 30, 2021-$2.57M–
Q1 FY2021Mar 31, 2021-$2.34M–
Q2 FY2020Jun 30, 2020-$3.53M–
Q2 FY2019Jun 30, 2019-$2.03M–

More Entera Bio figures

See a number that looks wrong?